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Introduction
Malignant pleural mesothelioma (MPM) still has a dismal
prognosis, and in the next 35 years it is calculated that about
one-quarter of a million deaths will occur as a result of this
disease in Western Europe [1].
History of asbestos exposure is reported in  70–80% of all
cases of mesothelioma and lifetime risk for exposed individ-
uals is up to 20% [2–4]. The two major species of asbestos,
crocidolite and chrysotile, are both hazardous. The workers at
extraction facilities are at the greatest risk of exposure and
development of asbestos-related diseases, but asbestos-cement,
insulation and shipyard workers are also at increased risk.
Environmental exposure to asbestos can occur as a result of
living in areas characterized by natural outcrops of asbestos or
asbestos-related materials, or those close to asbestos-produ-
cing or -using plants.
The disease mainly occurs in the fifth to seventh decade of
life, and in males more commonly than females (3.6:1).
Molecular biology
The molecular steps leading from asbestos within the parietal
pleura to the development of malignant mesothelioma are
mostly unknown and certainly numerous. However, it is well
known that in normal and premalignant cells, asbestos acti-
vates or inactivates a variety of genes, including the epidermal
growth factor receptor (EGFR), the insulin receptor and cell
cycle regulatory genes such as INK4a/ARF, as well as p16 and
NF2 genes [5]. Mutations of the p53 and ras genes, which are
frequently mutated in lung carcinomas, are rare in malignant
mesotheliomas. In contrast, SV40 Tag sequences are fre-
quently present but are absent in adjacent lung tissues and in
lung carcinomas [6, 7]. The biological and clinical signifi-
cance of this finding is not fully understood and, in addition,
some authors believe that the finding is attributable to an
underestimation of the contamination by common laboratory
plasmids containing SV40 sequences leading to false-positive
results [8].
Aberrant methylation of CpG islands in the promoter region
of tumor suppressor genes is a frequent mechanism of gene
silencing, but in malignant mesothelioma has received scant
attention. Methylation of RASSF1A has been linked to malig-
nant mesothelioma and correlates with poor outcome.
Aberrant methylation was more commonly observed in the
epithelial form of mesothelioma rather than in sarcomatous/
mixed types. Intriguingly, methylation in association with the
epithelial form of mesothelioma was found in patients whose
tumors showed SV40 Tag sequences. A profile of aberrant
methylation may help to distinguish between malignant
mesotheliomas and lung adenocarcinomas. For example,
methylation of adenomatous polyposis coli (APC) promoter
1A was completely absent in mesotheliomas, although it was
the gene most frequently methylated in adenocarcinomas
(52%) [9].
Pathology
Histologically, these tumors are composed of fibrous or epi-
thelial elements, or both. The epithelial subtype occasionally
causes confusion with peripheral adenocarcinoma of the lung
or metastatic carcinomas. Attempts at diagnosis by cytology
or needle biopsy of the pleura are often not contributive.
Thoracoscopy can be valuable in obtaining adequate tissue
specimens for diagnostic purposes. Immunohistochemistry has
recently become an essential diagnostic tool to differentiate
MPM from other types of cancer. Calretinin and keratin 5/6
are positive for malignant mesothelioma, whereas Ber-EP4,
CEA and Leu1 are negative.
Mesothelin is a 40-kDa cell surface differentiation antigen
present on normal mesothelial cells and overexpressed in sev-
eral human tumors, including mesothelioma, ovarian and
pancreatic adenocarcinomas [10]. However, mesothelin immu-
nostaining has a low specificity for discriminating between
epithelioid mesotheliomas and adenocarcinomas, and its use
may be considered in those instances in which the results
obtained with the standard panel of immunohistochemical
markers used for the diagnosis of mesotheliomas are inconclu-
sive. Because mesothelin is a highly sensitive positive marker
for epithelioid mesotheliomas, a negative staining for this
marker is an indication against such a diagnosis; however,
because of its limited utility, it is not recommended for
inclusion in the standard panel of immunohistochemical mar-
kers used in the distinction between mesotheliomas and
adenocarcinomas.
Clinical presentation
Dull, aching chest pain sometimes accompanied by cough,
dyspnea on exertion, fever, malaise and weight loss are the
most common presenting symptoms. Dullness to percussion
and decreased breathing sounds over the base of the affected
lung are the most common physical examination findings.
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Pleural and, in a later phase of the clinical history,
peritoneal effusions represent major symptomatic problems
for at least two-thirds of patients.
Death occurs after a median of 6–9 months as a result of
combinations of severe dyspnea, chest wall pain, abdominal
distention with ascites, intestinal obstruction, pericardial
tamponade, cachexia or pneumonia.
Diagnosis and staging
Computed tomography (CT) is usually the primary imaging
modality used for disease staging in patients who are being
considered for surgery. CT is readily available and provides a
significant amount of anatomic information. The results can
be used to preclude surgery in patients with obviously unre-
sectable tumors (e.g. diffuse extension of tumor into the chest
wall, mediastinum or peritoneum, or distant metastasis). Mag-
netic resonance imaging (MRI) or positron emission tomogra-
phy (PET) can then be used as the final preoperative
radiological examination to complement CT, particularly in
questionable cases. MRI with the use of different pulse
sequences and gadolinium-based contrast material can
improve the detection of tumor extension, especially to the
chest wall and diaphragm. PET is useful for the detection of
nodal involvement and occult metastasis. Correlation of all
imaging findings is essential in directing exploration to areas
of possible invasion and selecting those patients who may
benefit from aggressive therapy.
In addition to its role in diagnosis and staging, [18F]fluoro-
deoxyglucose (FDG) PET has several other advantages in the
management of MPM. Patients with MPM may have diffuse
pleural thickening but only focal areas of malignancy. Areas
of pleural thickening may not necessarily correspond to areas
of high metabolic activity, and the most appropriate biopsy
site may not be apparent from CT findings. Because FDG
PET can provide information about metabolically active areas
when findings are correlated with anatomic imaging infor-
mation, it may be used to help determine the most appropriate
biopsy site for obtaining positive results. Moreover, PET may
help predict prognosis in patients with MPM. A recent study
showed that MPM with higher FDG uptake is associated with
significantly shorter survival time. This information may be
clinically useful in determining whether to pursue an aggres-
sive therapeutic approach based on the biological features of
the tumor.
A histological diagnosis is required once MPM is suspected
radiologically. Neither cytological analysis of pleural fluid nor
needle aspiration biopsy of a pleural mass is diagnostic,
because it is extremely difficult to distinguish between cells of
MPM, metastatic adenocarcinoma and severe atypia. In con-
trast, CT-guided core needle biopsy has been shown to
improve diagnostic accuracy. Thoracoscopy or thoracotomy is
sometimes necessary, especially when a large core of tissue is
needed. Video-assisted thoracoscopic surgery has been shown
to have a diagnostic rate of 98%. Thoracoscopic evaluation
may also allow more accurate staging of MPM compared with
non-invasive methods such as CT and MRI. However, video-
assisted thoracoscopic surgery causes postprocedural chest
wall seeding in up to one-half of patients. Local postoperative
radiotherapy can prevent such seeding. In contrast, seeding
caused by imaging-guided biopsy is seen in no more than
22% of patients.
Small amounts of mesothelin can be detected in the blood
of some patients with mesothelin-positive cancers and
measurement of mesothelin in the blood may be useful for
the diagnosis and follow up of some of these patients. In a
blinded study, serum samples from 44 patients with histo-
logically proven mesothelioma, 68 matched healthy controls,
40 of whom had been exposed to asbestos, and 160 patients
with other inflammatory or malignant lung and pleural dis-
eases were tested for the presence of mesothelin-related pro-
teins. Eighty-four per cent of 44 patients with mesothelioma
had raised concentrations of mesothelin-related proteins,
compared with three (2%) of 160 patients with other cancers
or other inflammatory lung or pleural diseases, and none of
28 controls who had not been exposed to asbestos. Concen-
trations correlated with tumor size and increased during
tumor progression. Seven of the 40 asbestos-exposed indi-
viduals had increased serum concentrations of mesothelin-
related proteins; three of those seven developed mesothe-
lioma and one developed lung carcinoma within 1–5 years.
None of the 33 asbestos-exposed participants whose serum
samples had normal concentrations of mesothelin-related
proteins and who were followed up over 8 years developed
mesothelioma. Consequently, serum mesothelin could be a
useful marker for diagnosis of mesothelioma and to monitor
disease progression, and might also prove helpful for screen-
ing asbestos-exposed individuals for early evidence of
mesothelioma [11].
The new staging system from the International Mesothe-
lioma Interest Group is a tumor–node–metastasis (TNM) sys-
tem that was initially developed to categorize similar cases
into homogeneous prognostic groups to aid evaluation of new
treatment options (Tables 1–3) [12, 13]. This staging system
emphasizes criteria used to determine the extent of local
tumor and lymph node involvement, both of which factors
have been shown to be related to the overall survival rate in
MPM. With locally advanced tumors, it is important to dis-
tinguish between T3 (potentially resectable) and T4 (techni-
cally unresectable) disease. This distinction guides the choice
of treatment options and implies significant differences in sur-
vival. The presence of N3 nodal disease or distant metastasis
also precludes surgery. Although surgical staging is often
required in patients with potentially resectable lesions, CT,
MRI and PET can aid in choosing whether to treat MPM
surgically, medically or both.
Prognosis
Performance status and weight loss are powerful prognostic
factors in mesothelioma. Whereas male sex, older age, and
high platelet and leucocyte count have also been validated as
poor prognostic factors.
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Tumor-related prognostic factors involve the anatomical
extent of the tumor, and histological and biological character-
istics of the tumor. The oldest, most important biological mar-
ker of mesothelioma is the histology, a prognostic factor with
a major impact on survival. The survival of patients with an
epithelial type of mesothelioma might be twice the survival of
patients with a mixed or sarcomatoid type. This difference is
apparent in both surgical series and in patients who received a
non-surgical treatment. The invasive growth pattern of sarco-
matoid mesothelioma hampers surgical procedures and major
surgery is therefore not recommended in these patients.
Prognostic scoring systems have been proposed by the
European Organization for Research and Treatment of Cancer
(EORTC) [14] and by the Cancer and Leukaemia Group B
(CALGB) [15]. These systems were derived from statistical
analysis of large series of patients within chemotherapy trials.
Two EORTC risk groups were identified after multivariate
analysis of prognostic variables from 204 patients entered into
five consecutive trials. The factors included in the model
were: white blood cell count >8.3 109/l, Eastern Cooperative
Oncology Group performance status >_1, sarcomatoid tumor
cell type, probable or possible histological diagnosis, and male
sex. The high-risk group was defined by the presence of three
or more of these factors. The CALGB system is more complex
and derives from the analysis of 337 patients. A regression
tree leads to 11 groups, of which those with similar survival
characteristics are combined to form six prognostic groups.
Table 2. Node and metastasis descriptors for malignant pleural
mesothelioma
Descriptor Characteristics
NX Regional lymph nodes not assessable
N0 No regional lymph node metastases
N1 Metastases in ipsilateral bronchopulmonary or hilar
lymph nodes
N2 Metastases in subcarinal or ipsilateral mediastinal
lymph nodes, including ipsilateral internal mammary
lymph nodes
N3 Metastases in contralateral mediastinal, contralateral internal
mammary, and ipsilateral or contralateral supraclavicular
lymph nodes
MX Distant metastases not assessable
M0 No distant metastases
M1 Distant metastases
Table 1. Tumor descriptors for malignant pleural mesothelioma
Descriptor Region involved Characteristics
T1a Limited to the ipsilateral parietal pleura,
including the mediastinal and diaphragmatic pleurae
No involvement of the visceral pleura
T1b Ipsilateral parietal pleura, including the mediastinal
and diaphragmatic pleurae
Scattered tumor foci that also involve
the visceral pleura
T2 Each ipsilateral pleural surface At least one of the following:
(i) involvement of the diaphragmatic muscle; or
(ii) a confluent visceral pleural tumor (including fissures)
or tumor extension from the visceral pleura into
the underlying pulmonary parenchyma
T3 Locally advanced but potentially resected tumor
(each ipsilateral pleural surface)
At least one of the following:
(i) involvement of the endothoracic fascia;
(ii) extension into mediastinal fat;
(iii) a solitary, completely resectable focus of tumor that
extends into the soft tissues of the chest wall; or
(iv) non-transmural involvement of the pericardium
T4 Locally advanced, technically unresectable tumor (each
ipsilateral pleural surface)
At least one of the following:
(i) diffuse tumor extension or multiple tumor foci in
the chest wall with or without associated rib destruction;
(ii) direct transdiaphragmatic extension to the peritoneum;
(iii) direct extension to the contralateral pleura;
(iv) direct extension to the mediastinal organs;
(v) direct extension to the spine; or
(vi) extension to the internal surface of the pericardium
with or without pericardial effusion or involvement
of the myocardium
Table 3. Tumor–node–metastasis stage classification for malignant
pleural mesothelioma
Stage Tumor Node Metastasis
Ia T1a N0 M0
Ib T1b N0 M0
II T2 N0 M0
III Any T3 Any N1 or N2 M0
IV Any T4 Any N3 Any M1
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Treatment
Many new therapeutic modalities for MPM have been investi-
gated, either as single treatment approach or as combined
therapy. To date, there is no cure for MPM and consensus is
lacking on its best management. Physicians are faced with a
huge volume of conflicting literature, advocating diverse
options from palliation only to aggressive multimodality
therapy.
Age and co-morbidity often prohibit aggressive therapeutic
options in the individual patient. The median time lag between
asbestos exposure and development of MPM is >30 years,
hence most patients are relatively old at presentation. About
20% also have co-existing pulmonary fibrosis from asbestosis.
In addition, many patients are smokers with limited cardior-
espiratory reserve.
The number of MPM patients treated by surgery is still
rather small. Various surgical procedures may be possible in
selected patients, providing long-term survival without cure.
Although some patients with early-stage disease experience
long-term survival with aggressive treatment approaches
including extensive surgery, adjuvant chemotherapy and radio-
therapy, it remains unclear whether overall survival has been
significantly altered by the different treatment modalities or
by combinations of modalities. Extrapleural pneumonectomy
in selected patients with early-stage disease may improve
recurrence-free survival, but its impact on overall survival is
unknown. Pleurectomy and decortication can provide pallia-
tive relief from symptomatic effusions, discomfort caused by
tumor burden and pain caused by invasive tumor. Operative
mortality from pleurectomy/decortication is <2%, while mor-
tality from extrapleural pneumonectomy has been reported to
range from 6% to 30%.
For patients undergoing surgery the main prognostic factors
are male sex, high platelet count, and large preoperative and
postcytoreduction tumor volumes [16].
The use of radiotherapy in pleural mesothelioma has been
shown to alleviate pain in the majority of patients treated.
However, the duration of symptom control is short-lived [17].
Chemotherapy has been disappointing. EORTC examined
several cytotoxic drugs as mitoxantrone, epidoxorubicin, eto-
poside and paclitaxel, with no objective responses and median
survivals ranging from 6.7 to 9 months [14].
Single-agent and combination chemotherapy have been
evaluated in single and combined modality studies. Until
recently, the most studied agent was doxorubicin, which has
produced partial responses in 15–20% of treated patients.
Some combination chemotherapy regimens have been reported
to have higher response rates in small phase II trials; however,
the toxicity reported is also higher, and there is no evidence
that combination regimens result in longer survival or longer
control of symptoms [18].
In MPM, gemcitabine and cisplatin, given as single agents,
have shown response rates ranging from 7% to 14%, and
in vitro studies have suggested a synergic interaction between
these two compounds. A pivotal single institutional study
reported a response rate of 48% with this two-drug regimen
[19]. However, a larger phase II study by the same authors
[20] and additional phase II studies [21] have documented a
significantly lower level of efficacy.
Recently, pemetrexed has shown promising activity in
MPM. Pemetrexed is a folate antimetabolite that primarily
inhibits thymidylate synthase (TS). The penaglutamate form
of pemetrexed is the predominant intracellular form, and is
>60-fold more potent in its inhibition of TS. A phase I study
of pemetrexed plus carboplatin in 27 patients with stage III
and IV showed a response rate of 32% according to the strict
criteria of response assessment by measuring the thickness of
pleural tumor at three separate levels on transverse cuts on
each thoracic CT scan. Median time to progression was 10
months and median survival 15 months [22].
In a large phase III study, the combination of cisplatin and
pemetrexed was associated with significantly improved survi-
val time and with overall greater antitumor activity compared
with cisplatin alone. The regimen was well tolerated, particu-
larly in patients who received low-dose folic acid and vitamin
B12. Vitamin supplementation reduced toxicity with no appar-
ent adverse affect on efficacy [23].
Pharmacogenetic tests can contribute to elucidate which
patients can respond to a specific chemotherapy combination.
Overexpression of TS mRNA could correlate with resistance
to pemetrexed, and overexpression of nucleotide excision
repair genes such as ERCC1 mRNA correlates with resistance
to cisplatin or carboplatin.
Another antimetabolite, raltitrexed, was combined with
oxaliplatin and tested in 70 (15 pretreated and 55 chemo-
therapy-naı¨ve) patients with diffuse MPM. In the overall study
population, 14 patients (20%) had a partial response and 32
patients (46%) had stable disease. The symptomatic response
rates were as follows: shortness of breath, 36%; pain, 30%;
activity, 23%; appetite, 21%; and asthenia, 20%. Median time
to disease progression was 18 weeks and overall 1-year survi-
val was 26%. The most common adverse events were asthe-
nia, nausea/vomiting and paresthesia, and no treatment-related
deaths were reported [24]. An EORTC phase III trial com-
pared cisplatin plus raltitrexed versus cisplatin in 229 patients
with advanced MPM. Preliminary data indicate a non-statisti-
cally significant superiority of the combination in terms of
median survival time, but more mature data are needed [25].
Ranpirnase (Onconasew; p30 protein) is a novel RNAse
derived from frogs’ eggs. As ranpirnase treatment was associ-
ated with encouraging survival in certain subsets of patients
and showed an acceptable toxicity in a phase II trial [26], a
phase III study was designed. This study randomized 154
patients to receive either doxorubicin or ranpirnase. The
median and 1-year survival rates were similar in both arms:
7.7 versus 8.2 months, and 30.7% versus 32% (ranpirnase
versus doxorubicin). The authors assumed that these disap-
pointing data were caused by an excess of poor prognosis
patients in the ranpirnase versus the doxorubicin arm [27].
Vascular endothelial growth factor (VEGF) and platelet-
derived growth factor (PDGF) appear to be important
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autocrine growth factors for mesothelioma, and different strat-
egies aimed at blocking the autocrine loops have been recently
explored [28, 29]. Three VEGF inhibitors, SU5416, bevacizu-
mab and thalidomide, are currently evaluated in phase II
studies in mesothelioma patients. Imatinib mesilate and
PTK787, two PDGF-associated tyrosine kinase inhibitors, are
also under clinical investigation.
In addition,  70% of malignant mesotheliomas have high
level of expression of EGFR, and a subset of cell lines derived
from MPM patients express both EGFR and transforming
growth factor-a, suggesting an autocrine role even for EGFR.
However, two pivotal studies testing EGFR-tyrosine kinase
inhibitors have shown only limited level of activity [30, 31].
Chemical or thoracoscopic (either medical or video-
assisted) pleurodesis is useful in preventing fluid re-accumu-
lation and should be performed as early as possible.
Intrapleural administration of drugs or photodynamic
therapy allows direct delivery to the pleural surfaces, but
therapy administered in this manner usually fails to adequately
penetrate the tumor and underlying tissues.
With disease progression, trapped lung can occur with
tumor involvement of the visceral pleura. Once trapped lung
syndrome develops, pleurodesis is unlikely to be successful.
Small catheter drainage may provide an alternative to in-
patient pleurodesis, especially for patients with advanced dis-
ease, but carries the risk of tumor metastasis along the catheter
tract. Pleuroperitoneal shunting is not recommended because
of the potential risk of enhancing malignant spread to the
peritoneal cavity.
If dyspnea does not improve after adequate management of
the pleural effusion, supplementary oxygen and opioids may
help to reduce breathlessness.
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